Ovarian Cancer

Maintenance treatment with the novel agent niraparib improved progression-free survival (PFS) compared with placebo for patients with recurrent ovarian cancer harboring a germline BRCA (gBRCA) mutation or homologous recombination deficiency (HRD).

Testing for BRCA mutations is an important step in developing the treatment plan for patients with breast cancer, says Leslie Randall.

A program was launched to help ovarian cancer survivors combat sexual dysfunction they experience after treatment.

Women who received intraperitoneal chemotherapy after surgery for ovarian cancer had a reduced amount of disease progression when compared with those who received chemotherapy via IV.

According to a recent study, women with the BRCA1 mutation should not delay their pregnancies because their fertility may quickly decline once they enter their 30s.

According to an analysis of the phase 3 GOG-0218 trial, patients who had ovarian cancer and mutations in homologous recombination (HR) genes showed improved survival rates when compared to patients without the mutations.

Phase 3 studies are giving investigators hope that Lynparza (olaparib) will gain FDA approval for the treatment of ovarian cancer, according to Ursula A. Matulonis.

When finding out someone was recently diagnosed with ovarian cancer, don't respond by telling them the disease is lethal and has no symptoms.

At Bright Pink, we feel fortunate to hear stories each day from young women who are taking action when it matters most.

Knowing if a woman's ovarian cancer is genetic could have a huge impact not only on her treatment, but on her family as well.

Language and cultural barriers should not keep a patient from receiving and understanding their cancer care. SHARE Cancer Support steps in for people who face this struggle.

"HKASA is known as a one-stop online shop with a research-driven backbone for patients, caretakers, and the community affected by ovarian cancer."

With the overall number of deaths from cancer in decline over the past 20 years, advocacy groups like the National Ovarian Cancer Coalition are doing their part to reduce this number further.

Before losing her battle to ovarian cancer, Julie Paige McAvinn wanted to make sure other women were better educated about female cancers. Keeping his promise to his late wife, Peter McAvinn created the Julie Fund.

A Missouri jury has ordered Johnson & Johnson to pay $72 million in damages to the family of a woman who died from ovarian cancer, which she said was caused by products containing talcum powder.

Safran is the Executive Director of The Identity Shift Project, which aims to bring new perspectives to healing through collaborative art making.

Those who had taken birth control pills prior to their cancer diagnosis had improved progression-free survival compared with those who had not taken contraceptives.

Neoadjuvant chemotherapy is increasingly used in advanced ovarian cancer, even though it has not been shown to improve survival versus primary cytoreduction.

"It's not because there's evidence that they don't work — it's just that there's no evidence at all," Maurie Markman says.